SHP2: a new target for pro-senescence cancer therapies.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

6 citing papers in PubMed.

1. CK2 in triple-negative breast cancer: oncogenic signaling networks and emerging CK2 inhibitor-based combination therapies.Clinical and experimental medicine · 2026
   Review
2. Breaking the aging epigenetic barrier.Frontiers in cell and developmental biology · 2022
   Review
3. Mechanisms and significance of therapy-induced and spontaneous senescence of cancer cells.Cellular and molecular life sciences : CMLS · 2020
   Review
4. Senescent cells: an emerging target for diseases of ageing.Nature reviews. Drug discovery · 2017
   Review
5. p21 maintains senescent cell viability under persistent DNA damage response by restraining JNK and caspase signaling.The EMBO journal · 2017
   Article
6. Cellular senescence in aging and age-related disease: from mechanisms to therapy.Nature medicine · 2015
   Review

Corrections and comments

• Comment on
  Shp2 signaling suppresses senescence in PyMT-induced mammary gland cancer in mice.2015

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as